Literature DB >> 11745890

Bone mass after treatment of malignant lymphoma in childhood.

K Nysom1, K Holm, K F Michaelsen, H Hertz, J Müller, C Mølgaard.   

Abstract

BACKGROUND: Sex hormone deficiency, growth hormone deficiency, skeletal irradiation, and treatment with corticosteroids or methotrexate may all cause reduction in bone mass after treatment for childhood malignant lymphoma. Previous studies of the bone mass of childhood cancer survivors often lacked adequate local reference data, and survivors of malignant lymphoma were never analyzed separately. PROCEDURE: The bone mass of survivors of childhood Hodgkin disease (n = 23) or non-Hodgkin lymphoma (n = 21) was measured by dual-energy X-ray absorptiometry a median of 11 years after diagnosis (range 2-25). Results were compared with local data on 463 healthy controls.
RESULTS: Adjusted for gender and age, the mean whole-body bone mineral content and bone mineral areal density were slightly, but significantly, reduced (0.5 and 0.4 SD lower than predicted). The reduced bone mineral content was associated with a significantly reduced height, whereas the size-adjusted bone mass (bone mineral content for bone area) did not differ significantly from that of controls. Lower height was related to male gender and to cranial, thoracic, and lumbar spine irradiation. Whole-body bone mineral content and bone mineral density were lower in persons treated with lumbar spine irradiation and whole-body bone mineral content was higher in nine women receiving sex hormone replacement therapy or oral contraceptives. Whole-body bone mass was not related to the cumulated doses of corticosteroids or methotrexate.
CONCLUSIONS: Eleven years after diagnosis of childhood Hodgkin disease or non-Hodgkin lymphoma, the whole-body bone mass of survivors was only slightly reduced and the size-adjusted bone mass was normal. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745890     DOI: 10.1002/mpo.1245

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

1.  Predictors of bone loss in childhood hematologic malignancies: a prospective study.

Authors:  Ghada El-Hajj Fuleihan; S Muwakkit; A Arabi; L E-O Daouk; T Ghalayini; J Chaiban; M Abboud
Journal:  Osteoporos Int       Date:  2011-04-08       Impact factor: 4.507

2.  Pediatric Hodgkin lymphoma survivors at negligible risk for significant bone mineral density deficits.

Authors:  Sue C Kaste; Monika L Metzger; Anum Minhas; Zang Xiong; Shesh N Rai; Kirsten K Ness; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

3.  Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer.

Authors:  M A H den Hoed; B C Klap; M L te Winkel; R Pieters; M van Waas; S J C M M Neggers; A M Boot; K Blijdorp; W van Dorp; S M F Pluijm; M M van den Heuvel-Eibrink
Journal:  Osteoporos Int       Date:  2014-09-11       Impact factor: 4.507

4.  Modifiable risk factors associated with bone deficits in childhood cancer survivors.

Authors:  Lynda E Polgreen; Anna Petryk; Andrew C Dietz; Alan R Sinaiko; Wendy Leisenring; Pam Goodman; Lyn M Steffen; Joanna L Perkins; Donald R Dengel; K Scott Baker; Julia Steinberger
Journal:  BMC Pediatr       Date:  2012-03-28       Impact factor: 2.125

5.  Prediction of Low and Very Low Bone Mineral Density Among Adult Survivors of Childhood Cancer.

Authors:  Jenneke E van Atteveld; Saskia M F Pluijm; Kirsten K Ness; Melissa M Hudson; Wassim Chemaitilly; Sue C Kaste; Leslie L Robison; Sebastian J C M M Neggers; Yutaka Yasui; Marry M van den Heuvel-Eibrink; Carmen L Wilson
Journal:  J Clin Oncol       Date:  2019-05-31       Impact factor: 50.717

Review 6.  Pediatric DXA: clinical applications.

Authors:  Larry A Binkovitz; Paul Sparke; Maria J Henwood
Journal:  Pediatr Radiol       Date:  2007-04-13

7.  Bone mineral density, thyroid function, and gonadal status in young adult survivors of childhood cancer.

Authors:  Eryk Latoch; Katarzyna Muszyńska-Rosłan; Agata Panas; Anna Panasiuk; Beata Rutkowska-Żelazowska; Jerzy Konstantynowicz; Maryna Krawczuk-Rybak
Journal:  Contemp Oncol (Pozn)       Date:  2014-10-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.